Enhua Pharmaceutical (002262.SZ): Net profit of 265 million yuan in the first quarter increased 16.64% year-on-year

Gelonghui, April 19 | Enhua Pharmaceutical (002262.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1,358 million yuan, up 15.16% year on year; net profit attributable to shareholders of listed companies was 265 million yuan, up 16.64% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 267 million yuan, up 16.62% year on year; basic earnings per share were 0.26 yuan.

Gelonghui FinanceApr 19 03:51 ET

Is Jiangsu Nhwa Pharmaceutical (SZSE:002262) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is usu

Simply Wall StApr 17 21:56 ET

Enhua Pharmaceutical (002262.SZ): The new drug NVX-408 project is still in the pre-clinical research stage

Gelonghui, April 9, 丨 Enhua Pharmaceutical (002262.SZ) held a performance briefing on April 8, 2024 to discuss “Why has the new drug NVX-408 not progressed?” The company replied that the company's new drug NVX-408 project is still in the pre-clinical research stage.

Gelonghui FinanceApr 9 05:28 ET

Enhua Pharmaceutical (002262.SZ): The new drug Oselidine Injection (TRV130) achieved sales of around 18 million yuan last year

Gelonghui, April 9丨Enhua Pharmaceutical (002262.SZ) held a performance briefing on April 8, 2024 to discuss “How much was the new drug R130 sold last year, and how much was the gross profit?” The company replied that the new drug oselidine injection (TRV130) launched by the company achieved sales of around 18 million yuan last year, and the gross margin was slightly higher than the company's anesthetic products.

Gelonghui FinanceApr 9 05:28 ET

Enhua Pharmaceutical (002262.SZ): Gabapentin, risperidone, dexmedetomidine, and olanazepine participated in the collection

Gelonghui, April 9, 丨 Enhua Pharmaceutical (002262.SZ) held a performance briefing on April 8, 2024 to discuss “What products are currently participating in the collection?” The company replied that gabapentin, risperidone, dexmedetomidine, and olanazepam are equal.

Gelonghui FinanceApr 9 05:27 ET

Enhua Pharmaceutical (002262.SZ): Protolin nasal spray, an innovative drug to treat Alzheimer's disease, has completed phase I clinical trials and is expected to conduct phase IIa clinical trials in 2024

Gelonghui, April 9, 丨 Enhua Pharmaceutical (002262.SZ) held a performance briefing on April 8, 2024 to discuss “What stage has the company reached in the development of innovative drugs for Alzheimer's disease?” The company replied that up to now, the company's innovative drug Protolin nasal spray to treat Alzheimer's disease has completed phase I clinical trials, and it is expected that phase IIa clinical trials will be carried out in 2024.

Gelonghui FinanceApr 9 05:26 ET